Wilms tumor (nephroblastoma) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-BECKWITH-WIEDEMANN-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-WILMS`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025`

Notes

STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode. Standard-track BWS confirmed-carrier surveillance per Kalish 2017 / Brioude 2018 consensus. Disease anchor DIS-WILMS used; hepatoblastoma cancer-spectrum is described in rationale but does not currently have a DIS- anchor in the KB.

Used By

Indication

IND-BECKWITH-WIEDEMANN-CARRIER-INTENSIFIED - IND-BECKWITH-WIEDEMANN-CARRIER-INTENSIFIED